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Abstract. 
We report here the specific interaction between several members of the human 
galectin family with the three developmental stages of several genetic lineages 
of the protozoan parasite Trypanosoma cruzi. We provide data of specific and 
differential binding of human galectins-1, 3, 4, 7 and 8 to 14 strains of T. cruzi 
that belong to the six genetic lineages representing the genetic diversity of the 
parasite. It is shown that galectins preferentially bind forms present in the host, 
trypomastigotes and amastigotes, compared to the non-infective epimastigote 
present on the intestinal tract of the vector, reflecting the changes on 
glycosylation that occur during the metacyclogenesis and amastigogenesis 
process. Also, it is evidenced that galectin binding to the parasites promotes 
binding to the host cells and higher infection rates. In addition evidence is 
provided indicating that the intracellular amastigotes may take over the cytosolic 
pool of some galectins when released to the extracellular medium. Finaly, by 
applying unweighted pair group method analysis to the galectin binding profile 
to either cell-derived trypomastigotes or amastigotes we show that the 
differential binding profile by the host galectins to the six lineages resembles the 
clustering based in genetic data. Therefore, the differential binding profile for the 
six lineages could have implications in the immunopathology of Chagas’ 
disease, affecting the complex network of immune responses on which 
galectins mediate, thus providing linkage clues to the notion that different 
lineages may be related to different clnical forms of the disease.   
Introduction. 
 
Trypanosoma cruzi is the causative agent of Chagas’ disease or American 
trypanosomiasis, a chronic and debilitating multisystemic disorder that affects more 
than 8-10 million people in Latin America (World, O.H. 2010). The disease exhibits a 
diverse spectrum of clinical manifestations, starting with a short acute phase with 
variable parasitemia characterized by strong immunosuppression, followed by an 
indeterminate phase when no clinical symptoms are observed (Biolo, A., Ribeiro, A.L., 
et al. 2010, Coura, J.R. and Borges-Pereira, J. 2010, Rassi, A., Jr., Rassi, A., et al. 
2010). Nevertheless, a significant proportion of infected individuals develops a 
subsequent symptomatic chronic phase categorized in at least three clinical forms, in 
which the digestive (megacolon) and heart disease (chagasic cardiopathy) are the 
most common, but also involving skin (Hemmige, V., Tanowitz, H., et al. 2012) and 
nervous system disorders (Chuenkova, M.V. and Pereiraperrin, M. 2011, Py, M.O. 
2011). Interestingly, some geographical distribution is associatted to the disease 
clinical manifestations, perhaps reflecting the genetic variability of T. cruzi, and 
ultimately it may be also related to how the host immune response is elicited, including  
the pathogen sensing by the innate immune system, the perpetuation of inflammatory 
and autoimmune responses, as well as the ability to control parasitemia and chronic 
parasite persistence. However, the host factors responsible of triggering inmune 
mechanisms during disease initiation and progression still remain undetermined. T. 
cruzi has a complex life cycle with three different life forms (Brener, Z. 1973, de-Souza, 
W. 1984). The parasite is taken from infected mammals in the blood meal of the insect 
as blood trypomastigotes which undergo transformation to epimastigotes that migrate 
to the hindgut. After 3-4 weeks, they transform into infective non-dividing metacyclic 
trypomastigotes that are released in the feces onto skin or mucosa of the vertebrate 
host, where they are able to invade a wide variety of host mammalian cells, (de-Souza, 
W. 1984, Pereira, M.E. and Krettli, A.U. 1990). Once inside the cells, they transform 
into intracellular amastigotes, which then multiply till rupture of host cells, when they 
differentiate into bloodstream trypomastigotes that disseminate via lymphatocs and 
bloodstream, before going through another intracellular cycle or are taken up by the 
insect again closing the life cycle. In order to adapt and survive into these different 
environments, the parasite present very different composition of the plasma membrane 
and interestingly, the most dramatic changes are observed in the glycosylation profile 
of each biological form (Buscaglia, C.A., Campo, V.A., et al. 2006, de Lederkremer, 
R.M. and Agusti, R. 2009).  
Trypanosoma cruzi is a highly genetically diverse organism and it has been  
clustered into six Discrete Typing Units (DTUs) on genetic basis, that exhibit some 
degree of differential geographical distribution, virulence, tissue tropism and 
susceptibility/resistance to drugs (Aquilino, C., Gonzalez Rubio, M.L., et al. 2012, 
Macedo, A.M., Machado, C.R., et al. 2004). It has been suggested that the genetic 
polymorphism of the parasite population could be related to the diverse clinical 
manifestations of the disease (Macedo, A.M., Machado, C.R., et al. 2004). However, 
little is known about the host molecules involved on the differential parasite recognition 
and therefore, a systematic study is urgently needed to understand the multiple clinical 
outcomes of Chagas disease. Importantly, most of the pathogen-associated molecular 
patterns (PAMPs) described so far in T. cruzi are glycosylated (such as GPI-linked, 
mucins and trans-sialidases) and are indeed essential to control activation of the innate 
immune system and initiation of the acquired host immune response in the vertebrate 
host (Alcaide, P., Lim, Y.C., et al. 2010, Almeida, I.C., Camargo, M.M., et al. 2000, 
Nogueira, N.F., Gonzalez, M.S., et al. 2007, Previato, J.O., Wait, R., et al. 2004, 
Procopio, D.O., Almeida, I.C., et al. 2002). Therefore, characterization of the interaction 
between parasite glycans and their host’s putative Pattern Recognition Receptors 
(PRRs) is of outstanding relevance. Among the wide array of PPRs, galectins have 
attracted attention over the last years due to the large number of immune functions 
ascribed to them (Vasta, G.R. 2012). Galectins are an evolutionarily conserved family 
(so far 12 genes in humans) of animal lectins with preserved structure and calcium-
independent affinity for -galactosides (Vasta, G.R. 2012), yet exhibiting different fine 
specificity and affinity. They are widely expressed on diverse cell types, from immune-
privileged tissues to epithelial cells of intestinal tract. However, each one exhibitis a 
restricted tissue distribution (Nio-Kobayashi, J., Takahashi-Iwanaga, H., et al. 2009), 
and show a pleiotropic range of effects mainly related to inflammatory processes 
including but not limited to apoptosis, cell adhesion and migration, regulation of cell 
growth and pathogen recognition. Collectively, the final interplay of the galectin 
signalling network will be the cummulative result of each individual member interacting 
with its cognate ligands.It has become increasingly clear that different regulatory 
immune circuits can be associated to multiple activation of immune pathways triggered 
by PRRs (Amit, I., Regev, A., et al. 2011, Boonstra, A., Rajsbaum, R., et al. 2006, 
Chevrier, N., Mertins, P., et al. 2011, Dam, T.K. and Brewer, C.F. 2010, Dam, T.K. and 
Brewer, F.C. 2010, Trinchieri, G. and Sher, A. 2007). Hence, having several members 
of the galectin family to differentially scrutiny and mediate pathogen recognition 
constitutes a powerful mechanism to fine tune the subsequent immune response 
To date, there have been some reports suggesting that galectins are intimately 
linked to some aspects of T. cruzi infection, such as changes in expression of galectins 
and/or its ligands upon T. cruzi infection (Silva-Monteiro, E., Reis Lorenzato, L., et al. 
2007, Vray, B., Camby, I., et al. 2004, Zuniga, E., Gruppi, A., et al. 2001, Zuniga, E., 
Rabinovich, G.A., et al. 2001), including changes in subcellular location of gal-3 
(Machado, F.C., Cruz, L., et al. 2014, Reignault, L.C., Barrias, E.S., et al. 2014). It has 
also been shown that gal 3 is able to promote trypomastigotes adhesion to extracellular 
matrix components (Kleshchenko, Y.Y., Moody, T.N., et al. 2004, Moody, T.N., 
Ochieng, J., et al. 2000). However, the relevance of galectins in T. cruzi infection is still 
far from being resolved and there is no systematic study showing a direct interaction of 
specific galectins with neither different life forms of the parasite nor with individual T. 
cruzi lineages that often exhibit different pathology. 
Here we report the binding profile of several members of the human galectin 
family towards the three life forms of the human pathogen T. cruzi. Galectins present a 
higher affinity to biological forms found in the vertebrate host, such as trypomastigotes 
and intracellular amastigotes, compared to the non-infective epimastigotes present in 
the insect vector. Secondly, consistent with the role of galectins in the initiation of the 
immune response, by using unweighted pair-group method analysis of galectin binding 
profile of epimastigotes and cell-derived trypomastigotes of the six different DTUs,14 T. 
cruzi strains analysed could be arranged in five clusters that closely resembled the 
grouping based solely on genomic data. And last, we demonstrate that intracellular 
amastigotes are able to take over or “sequester” the soluble pool of intracellular host 
galectins that may affect the subsequent binding to non-infected host cells and the 
recognition by the host immune system. The implications of galectin-mediated 
recognition of T. cruzi on the evolution of parasite lineages and their differential 
outcome in Chagas pathology is discussed. 
  
Materials and methods. 
Cells and Parasites.  
Vero (Green monkey kidney epithelial cells, ATCC CCL-81), LLC-MK2 (Rhesus 
monkey, kidney epithelial cells, ATCC CCL-7), CaCo-2 (Human colorectal 
adenocarcinoma cells, ATCC HTB-37) and THP-1 (Human monocytes ATCC TIB-202) 
cells were grown in RPMI complete medium containing 5% FCS, 2 mM L-glutamine, 
penicillin (100U/ml) and streptomycin (100 g/ml) (Gibco, Grand Island, NY) at 37 ºC in 
an atmosphere containing 5% CO2. The mouse cardiac cell line HL-1 (Claycomb, W.C., 
Lanson, N.A., Jr., et al. 1998) was obtained and grown according to Dr. Claycomb 
(Department of Biochemistry & Molecular Biology, School of Medicine, Louisiana State 
University). 
All parasite strains listed in Table I were genotyped as described in (Zingales, B., Miles, 
M.A., et al. 2012) and DTU assigned according to the new consensus on nomenclature 
on genetic lineages of T. cruzi (Zingales, B., Andrade, S.G., et al. 2009). Epimastigotes 
life forms were continuously cultured in liver infusion tryptose medium supplemented 
with 5% fetal calf serum, and 0.01% hemin as described previously (Alcina, A. and 
Fresno, M. 1988). Cell derived trypomastigotes (CTT) were obtained from the 
supernatant of infected Vero cells at 4-6 days post-infection and isolated by differential 
centrifugation, and recovered from the supernatant after 2 hours incubation at 37ºC, 
this procedure was repeated once to reduce the proportion of intermediate forms and 
amastigotes. The final population was never less than 95% highly motile 
trypomastigotes. 
Amastigotes were obtained from 3-4 days infected Vero cells after lysis, either by 
Percoll discontinuous density gradient as described (Gamarro, F., Osuna, A., et al. 
1985) or by anion-exchange chromatography (Marques, A., Nakayasu, E., et al. 2011). 
Microscopic examination indicated that 98% or 95% respectively, of the population was 
homogeneous. No differences in the binding profile were detected. Given the highly 
consistent yield of the Percoll gradient method, it was the prefered method. 
Galectins.  
Expression plasmid pQE60 containing the human galectin-1 sequence was kindly 
provided by Dr. Elena Moisevaa (Leicester Warwick Medical School, UK). The protein 
was purified as described previously (Andersen, H., Jensen, O.N., et al. 2003). 
Expression plasmids for human galectin-3 and galectin-4 were provided by Dr. Hakon 
Leffler (Lund University, Sweden)(Patnaik, S.K., Potvin, B., et al. 2006). Expression 
plasmid pGEX containing the human galectin-7 sequence were provided by Dr. Thierry 
Magnaldo (Institut Gustave Roussy, France) (Magnaldo, T., Bernerd, F., et al. 1995). 
Four expression plasmids pGEX4T2 containing the human galectin-8 sequence and 
the mutant galectin-8 R69H, galectin-8 R233H, and galectin-8 R69H/R233H sequences 
were provided by Dr. Nozomu Nishi (Kagawa University, Japan) (Nishi, N., Shoji, H., et 
al. 2003).  All human recombinant galectins were expressed and purified from bacterial 
pellets as described in the original manuscripts and freed of LPS (Lipopolysaccharide) 
by passage on a polymixin-Sepharose™ column as described by the manufacturer. 
Briefly, bacteria cultures were incubated with 1mM isopropyl-1-thiogalactopyranoside 
for 3h at 37 ºC to induce recombinant protein production. Bacteria were pelleted, 
suspended in phosphate-buffered saline 4mM EDTA, 2 mM β-mercaptoethanol, 10mM 
lactose (PBS-MELac) together with a protease inhibitor cocktail. After sonicating, 
bacteria were centrifuged to obtain the soluble fraction. Recombinant galectins present 
in this fraction were purified by affinity chromatograph on -lactose-agarose and eluted 
with lactose 0.1 M and dialysed against a buffer containing 0.1mM -mercaptoethanol 
and 10M lactose. Once purified, each galectin was kept at -20ºC after freeze-drying 
solutions at concentrations above 10 Molar, in such way galectins were stable for a 
longer time avoiding proteolysis. Before each experiment, the integrity and purity of 
each galectin was assessed by SDS-PAGE and silver staining, and their sugar binding 
capacity was periodically tested (Figure 2 shows a representative silver stained gel of 
purified recombinant human galectins as used on this manuscript). Alexa-488-
conjugated galectins were prepared by labelling with Alexa Fluor 488 Microscale 
Protein Labelling Kit (Life Technologies) following manufacturer guidelines. 
Truncated galectin 3 was obtained as described before (Kopitz, J., von Reitzenstein, 
C., et al. 2001). 
Adhesion and infection assays of T. cruzi to host cells  
To study parasite-cell adhesion, THP-1 and LLC-MK2 were used. T. cruzi cell-derived 
trypomastigotes were labelled with the fluorescent dye CFSE according to 
manufacter’s instructions (carboxyfluorescein diacetate, succinimidyl ester, Life 
Technologies). THP-1 cells (106 cells/assay) were incubated with CFSE-labeled 
parasites in complete RPMI medium (cell:parasite ratio 1:3) for 15 min at 4ºC to 
prevent parasite internalization with or without recombinant galectins.. Then, cells were 
fixed in 1% paraformaldehyde in PBS. Samples were analysed by Flow Cytometry 
using a FACScalibur flow cytometer (BD Biosciences). Fluorescence associated to 
mammalian cell gating was quantified as an indication of cell-attached parasites. To 
study adhesion of T. cruzi to LLC-MK2 cell line, cells were cultured in microtiter plate 
wells and cell derived trypomastigotes were added to each cell in a 1:10 cell:parasite 
ratio, in the presence or absence of recombinant galectins (0.2-2µM) at 4ºC for 15 
minutes. After PBS washing, the number of parasites attached to the cells was directly 
counted in not less than 10 representative fields.  
Vero or LLC-MK2 cells growing on glass coverslips at 25% confluency in 24 well plates 
were used for infection assays. Cell-derived tripomastigotes were added at an infection 
index of 10 for 4 hours at 37°C, in the presence or absence of indicated galectins. The 
cells were washed three times to remove unattached parasites and kept at 37°C. 
At indicated times, cells were washed twice with PBS, fixed with Bouińs fixative 
solution and stained in Giemsa solution. The number of infected cells and number of 
intracellular amastigotes per cell were quantified counting at least 150 cells in three 
independent slides by two different observers. 
Flow Cytometry assays. 
Parasites were incubated with Alexa-488-labelled galectins (2 μM) for 15 minutes at 
4ºC. Unbound galectins were removed by washing three times with PBS, and parasites 
were then fixed in 1% paraformaldehyde for 20 minutes at 4ºC. Relative fluorescence 
intensity was measured on a FACScalibur flow cytometer (BD Biosciences) and data 
were analysed using FlowJo analysis software (Tree Star). 
Identification of T. cruzi galectin ligands.  
To prepare galectin immobilized columns, 5-10 mg of gal-3 and 4 (purified as 
previously described) were covalently coupled to HiTrap NHS-activated columns 
according to manufacturer’s instructions (Amersham Biosciences), including 5mM 
lactose in the coupling buffer. Gal-7-GST and gal-8-GST were coupled to glutation-
Sepharose columns. 
Membrane proteins of cell-derived trypomastigotes (Y strain) were obtained by labeling 
live parasites with Sulfo-NHS-SS-Biotin, lysed in buffer B (0.2 M NaCl, 20 mM Tris-HCl, 
0.1% CHAPS and protease inhibitors cocktail). The solubilized cell surface biotinylated 
proteins were purified by chromatography on a Neutravidin column (Pierce) and eluted 
with DTT 50mM. The eluted fraction was applied to columns containing the immobilized 
galectins. Columns were extensively washed with buffer B and buffer B plus 0.5M 
NaCl, and then specifically eluted with buffer B plus 100 mM lactose. The eluted 
material was resolved by SDS-PAGE, transferred to nitrocellulose filters and probed 
with biotinylated galectins.  
Identical nitrocellulose membranes lanes were cutted into 10 slices, reduced with 
dithiothreitol, alkylated with iodoacetamide and digested overnight with trypsin in a 1:40 
ratio. Peptides released were acidified with trifluoracetic acid (TFA, final 0.1%), dried 
and redisolved in 5 l TFA% and acetonitrile 33%. DHB (2,5-dihydroxybezoic acid) 0.5 
l was used as matrix and mixed with 0.5 l of peptide sample on a Anchor-chip 
(Bruker) and air dried. The spectra obtained were used for MASCOT in-house 
identification searches againstthe TryTrypDB T. cruzi protein database 
(Tcruzi_AnnotatedProteins-v7.0, http://TryTrypDB.org). The T. cruzi surface mucin 
AgC10 was identified among the galectin ligands by using a specific monoclonal 
antibody previously decribed by our laboratory (Alcaide, P. and Fresno, M. 2004a, 
Alcaide, P. and Fresno, M. 2004b). 
Confocal immunofluorescence microscopy.    
To study the subcellular location of endogenous galectins in infected cells, Vero cells 
were grown on cover slips to 25-30% confluence and then infected at an infection index 
(parasite:cell) of 10 with trypomastigotes, strain Y (DTU II), during 4h at 37 ºC, after 
which free parasites were removed by washing three times with medium before 
incubate them at 37 ºC in an atmosphere containing 5% CO2.  After 3 days, the cells 
were fixed with 1% paraformaldehyde-0.5% glutaraldehyde in buffer sodium cacodylate 
50 mM pH 7.1, 70mM NaCl, 0.1% saponin; washed three times with PBS-0.2% BSA, 
incubated with anti-galectin antibody and subsequently with Alexa-488-conjugated 
secondary antibody before images were acquired using Confocal LSM510 META 
microscope (Zeiss). 
Unweighted Pair-Group Method with Arithmetic Mean (UPGMA) Analysis 
The clustering was done using Pearson coefficient comparing the Medium 
Fluorescence intensity (MFI) of each DTU when tested against fluorescent conjugates 
of recombinant galectin 1, 3, 4, 7 and 8 by using DendroUPGMA (Garcia-Vallve, S., 
Palau, J., et al. 1999).  
  
Results. 
Galectins bind to Trypanosoma cruzi. 
First, we screened the binding of highly purified recombinant human galectins 
conjugated to Alexa-488 by flow cytometry to live epimastigotes, amastigotes and cell-
derived trypomastigotes. The purity of the recombinant galectins employed in the study 
was assesed by silver-stained SDS-PAGE gel (Figure 1). Individual life forms of T. 
cruzi were analyzed separately. Fig.2A shows a representative flow cytometry 
histogram obtained for the Y strain (DTU TcII) in which a differential binding profile is 
observed. There was a higher affinity (in terms of higher MFI) to the forms present in 
the host i.e.- cell-derived trypomastigotes and amastigotes, than to the non-infective in 
vitro cultured epimastigotes to which only gal-7 showed a binding clearly distinctive 
from negative controls. Gal-7 and gal-8 showed the higgest affinity when 
trypomastigotes were tested, whereas gal-1 and gal-4 were shown to bind amastigotes 
(Fig. 2B) in a clear indication of different glycan exposition on the different life forms, 
evidencing substancial differences in the specificity for each galectin. We did not find 
any quantitative difference between trypomastigotes obtained by metacyclogenesis or 
cell-derived trypomastigotes (not shown), suggesting that the change in the surface 
exposed glycans is inherent to the life form and not to the differentiation strategy used 
to generate them. The binding to cell-derived trypomastigotes was saturable, reaching 
a plateau at galectin concentrations close to 20M  (Fig. 2C) similar feature was found 
for amastigotes and epimastigotes (not shown). 
As galectins are soluble proteins located in the cytosol, it is reasonable to propose that 
the intracellular pool might bind to amastigotes exposing galactosides on their surface. 
In order to test this, purified extracellular amastigotes from disrupted-cell supernatants 
were galactose washed in order to remove any host galectin bound. Under those 
conditions, the binding of galectins to parasites was significantly increased for gal-1, 3 
and 7 (p< 0.01, Figure 3A). This is a clear indication that amastigotes are recruiting 
intracellular galectin (or any other galactoside-binding protein) from the infected host 
cells cytosolic pool. No significant difference was observed regarding gal-4 and 8. In 
contrast, when cell-derived trypomastigotes were subjected to the galactose wash; no 
increase in the MFI was found when compared to control non-washed trypomastigotes 
(Fig 3A), suggesting either they are not recruiting intracellular galectin or, the bound 
proteins are released/processed shortly after being exposed to the extracellular milieu. 
Another alternative is that trans-sialidase action makes any galactose exposed criptic 
for the galectins.  
The protein content obtained after galactose washing of isolated intracellular 
amastigotes was subjected to SDS separation and western-blot to detect host galectins 
by using specific antibodies or streptavidin-HRP to detect biotinylated-galectin 7 
(Figure 3B). As expected, when sucrose or mannose was used instead of galactose, 
galectins were not released from amastigotes, and it did not affect galectin binding 
observed by FACs (not shown).  
An alternative explanation to the “coating” with endogenous galectins as responsible 
for the diminished binding of exogenous galectins would be that the recently released 
amastigotes do not expose the galectin ligands and are unmasked or exposed 
immediately after being released in the media.  
In order to test this hypothesis, we set up in vitro infections of LLC-MK2 or Vero cells 
and after 4/5 days the cells were processed for immunofluorescence to examine the 
pattern of endogenous galectin distribution. Interestingly, non-infected cells expressed 
an uniform cytosolic staining pattern for gal-1, and 3 (Fig.4 D-E, arrow head), in clear 
contrast to infected cells where galectin expression was accumulated on the cell 
surface of intracellular amastigotes (Fig. 4A-B arrows), confirming that intracellular 
amastigotes are coated by host endogenous galectins. The possibility of a cross-
reacting endogenous parasite protein homologous to host galectin was ruled out by 
flow cytometry (as is shown in the controls in Fig.3A) and reports in the literature 
showing no specific cross-reactivity of anti-gal antibodies against T. cruzi antigens 
(Giordanengo, L., Gea, S., et al. 2001). 
Galectin binding to parasites is Carbohydrate Recognition Domain (CRD) 
dependent. 
Our data showed that the binding of galectins to T. cruzi was inhibited by lactose, but 
not sucrose, suggesting that the lactose-binding domain is involved in the parasite-
protein interaction. To confirm that the binding of the human galectins to the parasites 
was CRD-mediated, we next carried out the binding assays in the presence and 
absence of specific inhibitory ligands of galectins. Galectin binding was completely 
inhibited by lactose at 50 mM (Fig. 5A) or thiodigalactoside at 10 mM, indicating that 
the CRD was involved in the recognition to the sites exposed on the surface of the 
parasites. However, we failed to inhibit galectin binding when -galactosidase-treated 
parasites were used, perhaps as a result of an incomplete access of -galactosidase to 
the ligands due to steric hindrance from the dense mucin layers or/and to high protein 
turnover rate found in T. cruzi. 
Unambiguous evidence supporting the implication of the CRD for the tandem-repeat 
galectin-8, was obtained by using the recombinant human protein carrying punctual 
mutations (gal-8R69, gal-8R233 and gal-8R69R233, resulting in a non-functional N-
terminal, C-terminal and both N- and C-terminal CRDs respectively), that abolished the 
binding to their natural ligands (Nishi, N., Itoh, A., et al. 2006). Gal-8R69, and gal-
8R233 presented reduced binding to cell-derived trypomastigotes and an the null 
double mutant showed an absolute lack of binding, confirming that the CRD of gal-8 is 
directly involved in the binding to parasite ligands.  
Gal-3 is the only one member of the chimera-type galectin group, constituted by a CRD 
at the C-terminus and a collagen-like domain at the N-terminus that could bind T. cruzi 
in a CRD-independet manner. In order to determine which domain of gal-3 is 
responsible for the interaction with T. cruzi, we studied the binding properties of a 
truncated gal-3 constituted only by the C-terminus domain including the CRD after 
releasing the collagenous domain by collagenase treatment (Kopitz, J., von 
Reitzenstein, C., et al. 2001). As shown in Figure 5C, removal of the collagen-like N-
terminal domain does not affect the binding to trypomastigotes and amastigotes, 
indicating that the the recognition and binding of gal-3 to the parasite is also CRD-
mediated. .  
Galectin binding promotes adhesion to host cells.  
We next tried to address the functional relevance of the galectin-trypomastigote 
interaction on parasite adhesion and/or infection to host cells. To evaluate this we next 
performed in vitro adhesion and infection assays using several cell lines as models.  
Parasite adhesion to THP-1 cells in the presence of recombinant galectins was 
quantified by using a cell cytometry approach in which the gating of free CFSE-labeled 
live cell-derived trypomastigotes (strain Y) can be easily separated from unlabeled 
THP-1 cells according to their respective forward and size scatter values. Therefore, 
any increase in fluorescence in the cell´s gate is proportional to the number of CFSE-
labelled parasites that have been attached to those cells. Mixtures of parasites and 
cells in the presence or absence of galectins were submitted to analysis. We limited the 
analysis time to 15 minutes in order to look just for adhesion, and the temperature to 
below 16ºC to keep parasites live but blocking endocytosis of galectins, limiting 
protease activity. A positive correlation between the afinitty shown by individual 
galectins and their ability to promote parasite adhesion to host cells was observed (Fig. 
6A). Thus, gal-3, gal-7 and gal-8, the galectins that showed a higher affinity towards 
parasite infective forms, were those that promoted parasite adhesion to THP-1 cells, 
whereas, gal-1 and gal-4, with lower affinity towards trypomastigotes (strain Y), did not 
increase parasite adhesion to THP-1 cells compared to control (no exogenous 
galectin). Similar results were obtained with other different strains tested (data not 
shown). 
Like the galectin binding to isolated cells, the galectin-mediated adhesion of parasite to 
host cells was shown to be dependent on the CRD as it was abolished by specific 
haptens, such as lactose, or by mutation of both CRDs found in gal-8 (Fig. 6B).  
As monomeric gal-1 and gal-7 exhibited concentration-dependent oligomerization 
affecting their valency, we decided to test the effect of such functional aggregation 
concentration dependent on the binding. Thus, two concentrations of gal-1 and gal-7 
were tested; 0.2 M (mainly monomeric) and 2 M (mainly dimeric and/or higher 
oligomers). The data shown in Fig. 6C suggest that cell-binding promoting activity of 
this galectin relies on its multivalent properties acting as a molecular bridge between 
parasites and host cells.  
Similar assays were carried out with several adherent cell lines to mimic the 
phisiological enviroment found in vivo, where T. cruzi infects ephitelial cells, showing a 
broadly similar pattern of galectin induced adhesion (Fig. 6D).  
To further investigate the relevance of galectin-T. cruzi interaction, a new set of 
experiments was conducted to define whether the observed galectin-mediated 
adhesion to host cells translates into higher infection rates. Data shown in Fig. 7 
supports that idea, as in the presence of galectins, concomitant with an increased 
binding to the host cells, there is an increased infective ability evidenced by both the 
number of infected cells (Fig. 7A) and the number of amastigotes per cell (Fig. 7B). 
Identification of surface mucins as galectin ligands on T. cruzi. 
Once it was shown that galectins bind to T. cruzi, attempts to identify the galectin 
ligand on the parasite cell surface were carried out by using biotin-labeled recombinant 
galectins. It was detected a diverse array of protein bands ranging from 10 to 100 KDa, 
specific and variable for individuals galectins. A discrete band around 80-70 KDa was 
common for all galectins tested, however the total number of proteins detected was 
qualitatively different for each galectin (Fig. 8A). Gal-4 seemed to be the more 
restricted ligand galectin, with just the band around 80-70KDa detected in the eluate, in 
contrast to gal-1 that showed the most complex pattern of ligands. Interestingly, gal-7 
and gal-8 showed an almost identical pattern of ligands. To identify the parasite 
proteins contained in the samples, identical membranes were sliced and subjected to 
peptide mass fingerprinting. The identified proteins are shown in Table IV. By using 
specific antibodies again parasite mucins, the presence of the mucin AgC10 among the 
human galectin-7 and galectin-8 ligands was demonstrated (Figure 8B).  
Unweighted Pair-Group Median Arithmetic analysis. 
As galectins are relevant factors in the outcome of immune responses, we decided to 
test whether a differential galectin binding could be associatted to different DTUs 
described for T. cruzi, since DTUs are also associated to clinical manifestations. A 
similar binding pattern to different T. cruzi strains would indicate that inter-strain 
differences onexposed glycans are not significant and hence not being a discriminatory 
element, or by contrast, showing strain specific galectin binding (distingushing specific 
traits like type of galactose containing glycans exposed on the cell surface). In a similar 
fashion as the referenced strain Y, intracellular amastigotes and cell-derived 
trypomastigotes from the strains tested  (Table I) were the forms that showed the 
highest binding for all galectins tested. Furthermore, some differences were found 
when the Median Fluorescence Index (MFI) for each galectin binding profile was 
analysed (shown in Table II and III). Based on these differences, we decided to carry 
out an Unweighted Pair-Group Median Arithmetic (UPGMA) analysis of MFI values vs. 
DTUs to identify whether there was a common pattern for strains belonging to the 
same lineage. The resulting dendrogram shows that the 14 strains were grouped in six 
clearly discrete clusters when cell-derived trypomastigotes were analysed (Fig. 9A) and 
in five clusters when amastigotes were utilised (Fig. 9B) where the last cluster included 
strains from DTUs IV and V.  
  
Discussion. 
Specific interactions between galectins and glycoconjugates are considered to be 
critical determinants in pathogen recognition (Paz, I., Sachse, M., et al. 2010, 
Rabinovich, G.A. and Gruppi, A. 2005, Vasta, G.R. 2009). There is no direct evidence 
whatsoever regarding different galectins binding to the three life forms of this pathogen, 
and more important yet, there is no data on differential interaction of innate immune 
components (c-type lectins, galectins etc.) to different parasite genetic lineages. Under 
this premise, we decided to ascertain whether different human galectins are able to 
specifically recognize glycans exposed on the cell surface of the three life forms of the 
pathogenic parasite Trypanosoma cruzi.  
It is known that the parasite surface glycoconjugates are different in every biological 
stage of the parasite (Bourguignon, S.C., de Souza, W., et al. 1998, Colli, W. and 
Alves, M.J. 1999, de Lederkremer, R.M. and Agusti, R. 2009, de_Lederkremer, R.M. 
and Colli, W. 1995, Ferguson, M.A. 1997). Our results show that the life forms present 
in the host (amastigotes and trypomastigotes), are recognized to a greater extent than 
the non-infective epimastigotes, reflecting the changes that take place in membrane 
composition, accessibility and exposure of glycans on the infective forms, probably 
related to the infective capacity.  
The major glycoconjugates of T. cruzi, the mucins, are longer in the trypomastigotes 
and contain additional -galactopyranosyl residues (Almeida, I.C., Gazzinelli, R., et al. 
1999, Buscaglia, C.A., Campo, V.A., et al. 2006). Those changes are supposed to  
allow adaptation and survival in a new environment, where the parasite will encounter 
immune mechanisms controled by immune regulators, such as galectins. Whether the 
parasite evolved to display galectin ligands in the infective forms, or the host developed 
galectins with greater affinity towards infective form glycans is difficult to predict over 
the common evolutive pressure of both parts. In that context is worth mentioning that 
mannose receptor and mannose binding proteins have been described to favour 
binding of amastigotes to macrophages that had not been activated by IFN- (Kahn, S., 
Wleklinski, M., et al. 1995).  
We observe that intracellular amastigotes are the parasite form that binds galectins 
with the highest affinity. In that sense, it results interesting that intracellular amastigotes 
are “coated” with the citosolic soluble galectin pool from infected cells. It has been 
described an alternative infection cycle inside the host, where intracellular amastigotes 
released from lysate cells may initiate a new round of infection by attaching and then 
infecting neighbour cells. Besides altering the normal functions of citosolic galectins (by 
altering the intracellular pool), that galectin coating of amastigotes could favour a fast 
entry into neighbour cells by promoting adhesion and facilitating invasion with galectins 
acting as bridge between cells and parasites. Another possibility for the “decoration” 
with galectins would be to induce a receptor rearrangement of the galectin lattice at the 
host cell surface modificating in that way the signalling pathways that allow the 
amastigote to survive in the extracellular milieu before obligate transformation to 
trypomastigotes or initiate a new invasion cycle or simply tagging the amastigotes with 
a danger signal that favours the engulfment by macrophages. Whether this “coating” or 
“recruiting” of intracellular galectins confers to the parasite any advantage is just a 
matter of speculation at the moment. Remarkably, recent findings showed a 
recruitment of structures expressing gal-3 to vacuoles containing T. cruzi amastigotes 
(Machado, F.C., Cruz, L., et al. 2014, Reignault, L.C., Barrias, E.S., et al. 2014), and 
some reports showed that gal-3 covers intracellular Mycobacterium-containing 
phagosomes promoting pathogen killing (Beatty, W.L., Rhoades, E.R., et al. 2002). An 
intriguing alternative is that sequestering citosolic gal-3 may impair the phagocytic 
capacity of already infected cells by reducing actin cytoskeletal rearrangement (Sano, 
H., Hsu, D.K., et al. 2003). There are several reports showing the ability of galectins to 
bind to pathogens, sucha as viruses (Levroney, E.L., Aguilar, H.C., et al. 2005, Ouellet, 
M., Mercier, S., et al. 2005), bacteria (Barboni, E., Coade, S., et al. 2005, Fowler, M., 
Thomas, R.J., et al. 2006), (Mey, A., Leffler, H., et al. 1996), Candida sp., (Kohatsu, L., 
Hsu, D.K., et al. 2006), and the helminth Schistosoma mansoni (van den Berg, T.K., 
Honing, H., et al. 2004). In addition, gal-3 and gal-9 bind Leishmania major (Pelletier, I., 
Hashidate, T., et al. 2003, Pelletier, I. and Sato, S. 2002, van den Berg, T.K., Honing, 
H., et al. 2004). Regarding T. cruzi, only gal-3 has been described to interact with the 
parasite (Kleshchenko, Y.Y., Moody, T.N., et al. 2004, Moody, T.N., Ochieng, J., et al. 
2000) to promote adhesion to coronary artery smooth muscle cells and to extracellular 
matrix via a laminin bridge. Our data provide evidence that gal-3 binds T. cruzi 
amastigote surface, and for the first time we provide evidence that also other galectin 
members like gal-1, 4, 7, 8 can bind the parasite, preferentially amastigotes and cell 
derived trypomastigotes of all genetic lineages of T. cruzi. Of note, galectin binding 
may render more productive infections for the parasite protozoan. The relevance of T. 
cruzi-galectin interaction might vary depending on the individual galectin and on the cell 
type or matrix component that the parasite interacts with. If that is the case; our data 
suggest that T. cruzi could use different combinations of galectins to adhere and to 
infect cells in different tissues, perhaps reminiscent of the differential tropism exhibited 
by different lineages.  
Gal-7, located mainly on skin and stratified epithelia (Magnaldo, T., Bernerd, F., et al. 
1995, Magnaldo, T., Fowlis, D., et al. 1998)  is the only galectin that showed significant 
binding to the epimastigotes form. Epimastigotes are present on the vector and despite 
some reports showing infectivity (Burger, E., Lay, W.H., et al. 1982), they are generally 
considered to be non-infective The significance of this might be related to the presence 
of epimastigotes or metacyclic trypomastigotes excreted in the faeces (Schaub, G. and 
Losch, P. 1988). That opens the possibility that gal-7, located at the point of parasite 
entry, such as the skin, could have evolved to interact with parasite forms found there 
at the moment of infection, before new infective forms arise in the host. 
Using a classical approach of affinity chromatography allowed us to partialy identify, by 
peptide mass fingerprinting, a very limited and restricted group of membrane proteins 
from cell-derived trypomastigotes as ligands.Two proteins were found to be recognized 
by all the human galectins tested, the putative protease GP63, GP90. The  GP82, a 
putative mucin (TcMUCII) and a putative transialidase were also common ligand 
partners for the human galectins tested in this study. Using an alternative approach like 
western blot using soluble streptavidin-labeled galectins, in which the multivalency of 
galectins is preserved, we could observe many more unidentified ligands. A band 
around 70-80 KDa was the main T. cruzi trypomastigote ligand of all the galectins 
tested. We could identify just one potential ligand of gal-3, gal-7 and gal-8 as the mucin 
AgC10 (Alcaide, P. and Fresno, M. 2004a, Alcaide, P. and Fresno, M. 2004b, 
Kierszenbaum, F., Fresno, M., et al. 2002). Moody et al showed a 45KDa parasite 
mucin that was detected as a gal-3 ligand (Moody, T.N., Ochieng, J., et al. 2000) that 
could be AgC10. Gal-3 could be implicated in the immunosupressor activities attributed 
to the mucin, as is known that gal-3 modulates T cell responses by control of TCR 
clustering at the immune synapse (Demetriou, M., Granovsky, M., et al. 2001). Other 
galectins might be concerned as it could bind to common receptors (Patnaik, S.K., 
Potvin, B., et al. 2006), although the biological functions derived from different 
transduction signals must not be necessarily the same.  
As galectins are multivalent proteins, they can cross-link receptors mediating cell-cell 
adhesion and/or cell-extracellular matrix. Therefore, experiments were conducted to 
evaluate the ability of galectins to promote parasite adhesion to host cells. The 
galectin-induced adhesion was both concentration- and CRD-dependent. When gal-8 
null mutant was used, adhesion was abrogatted, suggesting that an active CRD is 
required to favour parasite adhesion to host cells. Nevertheless, the gal-8 mutant that 
has a non-functional N-terminal domain, gal-8R233, is still able to promote parasite 
adhesion to host cells, although in a lesser extent than the wild type. Gal-8R233 is 
supposed not to cross-link glycosylated receptors, as only one terminal domain of the 
protein keeps carbohydrate recognition domain. It could be argued that the mutated 
CRD interacts with some host molecules in a sugar independent way. However, that is 
not occurring in the parasite binding because lactose inhibits wild type gal-8 binding to 
the parasite. Another explanation, although galectin-8 is a tandem repeat, is that the 
protein can form homodimers through the N-terminal CRD, as it has been published 
before (Stowell, S.R., Arthur, C.M., et al. 2008). In that way gal-8 could still bind with 
relative high affinity to cognate ligands.  
A way in which the galectin binding to the parasites could be modified is by altering the 
galectin ligands exposure, for example by -galactosidases or the sialyltransferase ST6 
(Zhuo, Y. and Bellis, S.L. 2011) acting as negative regulators. It could be argued that 
the transialidase (TS) from T. cruzi, considered a virulence factor, could act as such 
modulator, but that is not the case as the TS does not transfer sialic acids linked 2-6 
(Vandekerckhove, F., Schenkman, S., et al. 1992) and hence could not modify the 
galectin binding to host self-ligands, however there are no reports of T. cruzi -
galactosidase as virulence factor. 
By evaluating whether different reference strains with clearly distinct biological 
behaviour exhibit differential binding to host immune proteins like galectins, support to 
the notion that specific traits in the different genetic lineage or DTUs of T. cruzi could 
be associated to differential pathology is provided. If there is a differential galectin 
binding profile for each genetic lineage, that could mean that different immune 
responses networks would be triggered at different tissues and eventually be correlated 
to the differential course of the Chagas’ disease pathology. This analysis allowed to 
build a tree with six groups clearly defined, that closely resembles the one built solely 
on genetic data.  
A parallel analysis taking the similarity matrix build on amastigote-galectin binding 
profile data arranged the different lineages in five clusters contaning each one a single 
DTU and a mixed cluster containing DTUs IV and V together.  
Our findings are compatible with the idea that DTUs II (arranged in the tree far apart 
from the rest) and I are ancient parental lineages and that DTUs IV and V are recent 
ones derived from at least one recombination event (one cluster together or very 
close). This is to our best knowledge the first report of clustering the DTUs based on 
biological properties. 
A great limitation of UPGMA is that it assumes the same evolutionary speed on all 
lineages, i.e. the rate of mutations is constant over time for all lineages in the tree, and 
so we must be very cautious implying that the rate of changes in glycan modifications 
on each lineage is constant and that the distances reflect true evolutionary distance. It 
is clear that further studies including more strains and isolates is necessary before any 
conclusions  can be raised. 
The results also reflect changes in the composition and quantity (ratio of enzymes 
involved in synthesis/modification of glycans) of “glycogenes” in the lineages genomes.  
It must be considered here that glycoconjugates are not direct products of the genome, 
but the result of a series of variable sequences of “glycogenes” actions, and subtle 
changes on them may result in a great diversity of structures, and for sure such 
variations may have profound implications in virulence, antigenicity and immune 
response deriving in variable pathogenesis (Varki, A. 2011).  It is known that T. cruzi 
lineages (Araujo, C.A., Mello, C.B., et al. 2002), or different strains showing dissimilar 
infectivity/virulence (Piazza, R.M., Borges, M.M., et al. 1996) can be distinguished in 
vitro by their diferent affinity towards PNA, suggesting that different lineages exhibit 
different glycans on their surface. This has been recently confirmed by (Soares, R.P., 
Torrecilhas, A.C., et al. 2012) showing differential expression of -galactosyl residues 
in T. cruzi GPI-mucins, and by our group showing differential glycan profile by different 
strains of T. cruzi (Bonay and Staudacher, manuscript in preparation).  
The composition of lineages in a natural infecting population may play a role in 
determining the outcome of the infection and may reflect the differential interaction with 
host proteins regulating the immune response. Providing evidence of discriminant 
reactivity of a family of immune relevant proteins against different lineages imposes 
new views on the causes and progression of the wide spectra of disorders associated 
to the disease. In addition, it reinforces the notion that differential outcomes of T. cruzi 
infection could be influenced by the complexity of the infecting T. cruzi population that 
interferes with host factors related to regulation of acute inflammatory response 
essential for protection against infection, but may also contribute to pathology. This 
represents the first step to extend this analysis to another relevant protein in order to 
increase the view on how the innate immune system perceives the different 
parasites/strains and thus provides a clue to elaborate complex networks of 
interactions and deciphers the fine-tuning events occurring with complex pathogens.  
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Figure legends. 
 
 
Figure 1: Purified galectins are shown after SDS-PAGE. 
Samples of each purified recombinant galectin (between 1-3 g) were separated by 
SDS-PAGE in a 12% gel and silver stained. 
  
Figure 2: Human recombinant Galectin binding to T. cruzi (strain Y, DTU II) is 
specific for different biological stages. 
Alexa488-labeled recombinant human galectins were incubated with three parasite life 
cycle stages at 4ºC and galectin binding was quantified by flow cytometry.  
A) Alexa-488-galectins were able to bind T. cruzi, and the affinity of galectins was 
higher for the infective forms of the parasites under the same experimental conditions. 
Parasites incubated with galectins are shown in solid black, unlabeled negative 
controls in white. 
The insets show a representative micrograph of the parasite population employed for 
each analysis. 
B) Mean of fluorescence intensity (MFI) of galectins (5M) binding to the three life 
forms. Median ± SD of five independent experiments is shown. 
C) MFI of Alexa-488-labeled recombinant human galectins 1, 3, 7 and 8 bound to cell 
derived trypomastigotes vs galectin concentration. The median ± SD of five different 
experiments is shown 
 
Figure 3 Amastigotes and cell derived trypomastigotes bind host galectins. 
A) Amastigotes or cell derived-trypomastigotes were washed with lactose or sucrose as 
described in Materials and Methods before being submitted to Flow Cytometry analysis 
of galectin binding. 
The median ± SD of three different experiments is shown. 
* indicates significant at p<0.05 
B) Wash media from amastigotes recovered by centrifugation and filtration on 0.22 M 
was resolved by SDS-PAGE and WB with specific anti-galectin antibodies (for galectin-
1 and 3) or streptavidin-HRP for biotinylated galectin-7. 
 
 
Figure 4:  Intracellular amastigotes bind intracellular pool of galectins. 
LLC-MK2 cells (Panel A, C and D) or Vero (Panel B, E and F) growing onto glass 
coverslips were infected as described. After four days p.i., the cells were processed for 
immunofluorescence and stained with anti galectin 1 (A and B), galectin 3 (D) and 
galectin 7 (E) or just seconday antibody (C and F). 
 
Figure 5: Galectin binding to trypomastigotes is mediated by the CRD. 
A) Negative controls are in solid grey, thin black line refers to parasites after incubation 
with FITC-galectins, 2 μM, for 15 minutes at 4ºC. Parasite-associated fluorescence was 
quantified by flow cytometry. In the case of galectin-7, the thicker black line (-) 
corresponds to a galectin concentration of 20 μM, and the thin line (-) to 2 μM. 
B) Metaciclic trypomastigotes were incubated with FITC labeled galectin-8, and with 
the FITC labelled mutants R69, R233 and R69R233 for 15 minutes at 16ºC. The mean 
of fluoresce intensity was measured by flow cytometry. All the mutants showed a 
reduced binding capacity to T. cruzi. 
C) Flow cytometry analysis of truncated galectin-3 binding to trypomastigotes of T. 
cruzi strain Y. Negative control (no gal-3, white), full length galectin-3 (grey trace), 
truncated C-terminal CRD of galectin-3 (black trace).  
 
Figure 6: Recombinant human galectins promote parasite adhesion to host cells. 
A) Cell-derived trypomastigotes (strain Y) were labeled with CFSE, and incubated with 
non-labeled cells. Parasites and cells were resolved by flow cytometry due to their 
different size, and the fluorescence intensity associated to the cell gate (THP- 1) was 
quantified. Almost 100% of the parasites presented high fluorescence intensity, and 
only 6% of the cells showed fluorescence intensity when incubated with parasites in the 
absence of rGals.  
B) Aliquots of galectin-8 was added to the mixture of cells and parasites for 10 minutes 
at 16ºC, and the rate of positive cells increased to 43.9% of the total. This binding was 
abolished in the presence of lactose 50 mM, or when galectin-8 R69, R233 and 
R69R233 were used instead of the wild type galectin. C) Mean fluorescence intensity is 
shown using the same approach with gal-1,-3,-4,-7 and -8, at 0.2 μM and 2 μM, in the 
presence and absence of lactose. Representative results from two independent 
experiments performed is shown. D) Cell-derived trypomastigotes (strain Y, DTU II) 
were incubated with a LLC-MK2, CaCo and HL-1 cells monolayer for 15 minutes at 
16ºC in the presence or absence of 2 μM recombinant galectin, after extensive 
washing, the attached parasites were counted. 
 
 
 
 
Figure 7: Galectin binding promotes productive infections 
Cell-derived trypomastigotes (strain Y, DTU II) were incubated with LLC-MK2 cells for 
15 minutes at 16ºC in the presence or absence of 2 μM recombinant galectin, after 
extensive washing, the cells were incubated at 37º for up to five days. At indicated 
times; cells were washed twice with PBS, fixed with Bouińs fixative solution and stained 
in Giemsa solution. The intracellular amastigotes were quantified by counting randomly 
at least 300 cells. 
 
Figure 8: Identification of parasite galectin ligands  
A) Cell-derived trypomastigote protein extracts were applied to inmobilized galectin 
columns, washed extensively and eluted with 100mM lactose, resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and blotted with biotin labeled recombinant 
galectins, and revealed with streptavidin-HRP.  
B) Either Gal-7-GST or Gal-8-GST was immobilized to Glutation-Sepharose® and cell-
derived trypomastigote extracts were applied. GST immobilized was used as a control. 
After extensive washing, the column was eluted with 100mM lactose. Eluted fractions 
were subjected to western-blot using specific antibodies against T. cruzi mucin AgC10.  
1: Gal-7-GST column lactose elution, 2: Gal-8-GST column lactose elution, 3: GST 
column lactose elution, 4: Blank Sepharose lactose elution, 5, 6: washing elutions, 7: 
purified AgC10. 
 
Figure 9. UPGMA analysis of galectin binding profiles. 
A matrix was built with the data shown in Table II and III, presenting the Median 
Fluorescence Index (MFI) for the binding of each galectin to cell-derived 
trypomastigotes (A) or amastigotes (B) of each parasite strain in order to construct a 
dendrogram reflecting relationships between the different T. cruzi DTUs represented by 
the reference strains used in this study.  
  
 
Table I 
 
Strains of T. cruzi used in this work.  
 
Strain DTU Origin Host/Vector 
Silvio/X10 c1 I Belem, Brazil Homo sapiens 
Dm28c I Carabobo, Venezuela Didelphis marsupialis 
Esmeraldo c3 II Bahia, Brazil Homo sapiens 
Y II Sao Paulo, Brazil Homo sapiens 
Tu18 c2 II Tupiza, Bolivia Triatoma infestans 
Cm17 III Carimaga, Colombia Dasyprocta fugilinosa 
M6241 c6 III Para, Brazil Homo sapiens 
Can III c11 IV Para, Brazil Homo sapiens 
10R26 IV Santa Cruz, Bolivia  Aotus sp. 
Bug2148 c11 V Rio Grande do Sul, 
Brazil 
Triatoma infestans 
Sc43 c1 V Santa Cruz, Bolivia Triatoma infestans 
Tula c2 VI Tulahuen, Chile Homo sapiens 
VFRA c1 VI Francia, Chile Triatoma infestans 
CL-Brener VI Rio Grande do Sul, 
Brazil 
Triatoma infestans 
 
 
  
Table II 
 
 
Strain DTU MFI gal-1 MFI gal-3 MFI gal-4 MFI gal-7 MFI gal-8 
Silvio/X10 c1 TcI 15±3 48±5 14±4 48±4 19±4 
Dm28c TcI 17±4 47±7 15±5 51±9 22±5 
Esmeraldo c3 TcII 15±3 19±4 16±7 80±6 30±8 
Y TcII 18±4 15±6 19±5 77±8 26±6 
Tu18 c2 TcII 17±5 18±4 21±6 75±8 28±9 
Cm17 TcIII 19±3 38±5 20±5 55±7 39±7 
M6241 c6 TcIII 22±5 39±7 24±6 60±10 41±6 
Can III TcIV 28±7 38±5 19±7 65±8 46±7 
10R26 TcIV 35±7 37±6 18±8 57±10 31±8 
Bug2148 c11 TcV 18±5 40±5 16±7 68±6 31±3 
Sc43 c1 TcV 19±5 42±3 19±4 78±7 32±2 
Tula c2 TcVI 20±5 26±6 21±5 57±5 21±3 
VFRA c1 TcVI 21±4 28±2 22±8 49±4 20±3 
CL-Brener TcVI 19±3 27±4 25±4 55±4 24±3 
 
Median fluorescence Intensity (MFI) for each galectin-FITC against cell derived 
trypomastigotes from the indicated strains. Each flow cytometry analysis was carried out 
three times and the median ± SD is shown. 
  
Table III 
 
 
Strain DTU MFI gal-1 MFI gal-3 MFI gal-4 MFI gal-7 MFI gal-8 
Silvio/X10 c1 TcI 19±7 25±4 91±10 78±8 47±8 
Dm28c TcI 27±5 27±6 87±8 71±7 41±9 
Esmeraldo c3 TcII 87±5 29±8 125±10 79±3 30±8 
Y TcII 78±8 31±5 94±8 58±9 21±4 
Tu18 c2 TcII 97±7 35±9 130±12 75±8 28±9 
Cm17 TcIII 45±6 88±43 150±11 98±8 61±7 
M6241 c6 TcIII 41±8 97±6 112±9 87±11 71±8 
Can III TcIV 39±6 65±7 75±8 99±7 44±8 
10R26 TcIV 45±4 59±8 85±7 125±15 43±3 
Bug2148 c11 TcV 54±7 71±2 67±4 98±3 41±8 
Sc43 c1 TcV 61±3 81±3 57±9 108±11 29±7 
Tula c2 TcVI 27±4 52±8 90±4 57±5 31±5 
VFRA c1 TcVI 32±8 68±3 81±9 65±3 40±6 
CL-Brener TcVI 39±7 77±9 78±10 70±7 38±7 
 
 
Median fluorescence Intensity (MFI) for each galectin-FITC against amastigotes from the 
indicated strains. Each flow cytometry analysis was carried out four times and the 
median ± SD is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV. 
 
 Protein (MW) Sequence of identified peptide  Accession number 
Galectin1 Surface Protease GP63 
putative 
R.GRPVVGVINPR.H 
R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I 
R.LLVRPLDGPLVVPR.F 
R.SSVHVVNSR.N 
R.FREGSVCGK.F 
Q4CM87 
 GP90 K.AYTVLGPTDGTDNRVGFFYHPTTTTK.L 
K.QSTIDAHEVK.L 
K.LTESDSEVMWPVNTR.V 
K.VFLLVGSLGELK.E 
R.EPTDSEPTGGITWGEIK.S 
AAM47176 
 GP82 R.GEIDAQYAVDGK.L 
K.GNLDVVLSPTTTMK.G 
R.KVMLYTQR.G 
ABR19835 
 Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1 
 Calcium-binding protein K.VEDPAALFK.E 
K.LDEFTPR.V 
BAA13411.1 
 Surface protein-1 K.APSESTPLLGAGLGDNDGTK.F AAB18265.1 
 Trans-sialidase, putative K.SLLGQIAPQAQGDSK.V 
K.NFFLYNRPLSADELK.M 
EAN98599.1 
Galectin3 Surface Protease GP63 
putative 
R.LLVRPLDGPLVVPR.F 
K.VDILENVILSEAAK.M 
Q4CM87 
 GP90 K.AYTVLGPTDGTDNRVGFFYHPTTTTK.G 
K.LTESDSEVMWPVNTR.V 
K.TTESGTWEPGKEYQVAL.M 
R.KVMLYTQR.G 
R.EPTDSEPTGGITWGEIK.S 
AAM47176 
 GP82 K.LVVGEVTKPSAGGEPSG.W 
K.FTGFGSGAIWPVNNR.E 
ABR19835 
 Trans-sialidase, putative K.SLLGQIAPQAQGDSK.V EAN98599.1 
Galectin4 Surface Protease GP63 R.LLVRPLDGPLVVPR.F Q4CM87 
putative R.SSVHVVNSR.N 
R.FREGSVCGK.F 
R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I 
R.VAVHEM*AHALGFIVTDM*EGQALVK.R 
K.VDILENVILSEAAK.M 
 GP90  K.GELSSSLLYSDGNLQLLQQR.G 
R.VGFFYHPTTTTK.G 
K.SQSFFSDLK.L 
R.EPTDSEPTGGITWGEIK.S 
K.EDGENCLLSTGVSPAK.C 
AAM47176 
Galectin7 Surface Protease GP63 
putative 
K.VDILENVILSEAAK.M 
R.LLVRPLDGPLVVPR.F 
R.FREGSVCGK.F 
Q4CM87 
 Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1 
Galectin8 Surface Protease GP63 
putative 
R.FREGSVCGK.F 
R.LLVRPLDGPLVVPR.F 
Q4CM87 
 GP90 R.KVMLYTQR.G 
K.LTESDSEVMWPVNTR.V 
K.AYTVLGPTDGTDNRVGFFYHPTTTtK.G 
R.EPTDSEPTGGITWGEIK.S 
AAM47176 
 GP82 K.NVFLYNPRPLGADELR.M 
K.FTGFGSGAIWPVNNR.E 
K.GNLDVVLSPTTTMK.G 
ABR19835 
 Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1 
 
Proteins from T. cruzi cell-derived tripomastigoes (strain Y) bound to galectins. 
